Drugs / HMPL-415S1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05886374 | Jul 2023 → May 2025 | cancer | Hutchmed | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-415S1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886374 ↗ |
| Route | Oral | “HMPL-415S1 will be administered orally once daily in 28 days treatment cycles” NCT05886374 ↗ |